327 related articles for article (PubMed ID: 35414354)
21. Pentasaccharides for the prevention of venous thromboembolism.
Dong K; Song Y; Li X; Ding J; Gao Z; Lu D; Zhu Y
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005134. PubMed ID: 27797404
[TBL] [Abstract][Full Text] [Related]
22. A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists.
Touma L; Filion KB; Atallah R; Eberg M; Eisenberg MJ
Am J Cardiol; 2015 Feb; 115(4):533-41. PubMed ID: 25547937
[TBL] [Abstract][Full Text] [Related]
23. Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants: A systematic review and meta-analysis.
Chen H; Tao R; Zhao H; Jiang J; Yang J
Medicine (Baltimore); 2020 Jan; 99(5):e19000. PubMed ID: 32000440
[TBL] [Abstract][Full Text] [Related]
24. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
Arce-Huamani MA; Barboza JJ; Martínez-Herrera JF; Torres-Roman JS; Maguiña JL
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893585
[No Abstract] [Full Text] [Related]
26. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
27. Anticoagulation for people with cancer and central venous catheters.
Akl EA; Ramly EP; Kahale LA; Yosuico VE; Barba M; Sperati F; Cook D; Schünemann H
Cochrane Database Syst Rev; 2014 Oct; (10):CD006468. PubMed ID: 25318061
[TBL] [Abstract][Full Text] [Related]
28. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
[TBL] [Abstract][Full Text] [Related]
29. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis.
Alhousani M; Malik SU; Abu-Hashyeh A; Poznanski NJ; Al-Hasan S; Roth DF; Alsharedi M; Mustafa B
Thromb Res; 2021 Feb; 198():103-114. PubMed ID: 33310644
[TBL] [Abstract][Full Text] [Related]
30. Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty.
Suen K; Westh RN; Churilov L; Hardidge AJ
J Arthroplasty; 2017 Sep; 32(9):2911-2919.e6. PubMed ID: 28522244
[TBL] [Abstract][Full Text] [Related]
31. Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism.
Hannevik TL; Brekke J; Enden T; Frøen H; Garresori H; Jacobsen EM; Paulsen PQ; Porojnicu AC; Ree AH; Torfoss D; Velle EO; Wik HS; Ghanima W; Sandset PM; Dahm AEA
Thromb Res; 2020 Dec; 196():238-244. PubMed ID: 32919178
[TBL] [Abstract][Full Text] [Related]
32. Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials.
Loffredo L; Violi F; Perri L
Int J Cardiol; 2016 Jun; 212():255-8. PubMed ID: 27057930
[TBL] [Abstract][Full Text] [Related]
33. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials.
Frere C; Farge D; Schrag D; Prata PH; Connors JM
J Hematol Oncol; 2022 May; 15(1):69. PubMed ID: 35598026
[TBL] [Abstract][Full Text] [Related]
34. Comparative Efficacy of Oral Apixaban and Subcutaneous Low Molecular Weight Heparins in the Treatment of Cancer-Associated Thromboembolism: A Meta-Analysis.
Baloch MF; Adepoju AV; Falki V; Hajjaj M; Habet T; Habet K; Mahrosh A; Kundu S; Kataria J; Mathew M; Saka T; Al-Tawil M
Cureus; 2023 Aug; 15(8):e43447. PubMed ID: 37711939
[TBL] [Abstract][Full Text] [Related]
35. Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials.
Marcucci M; Etxeandia-Ikobaltzeta I; Yang S; Germini F; Gupta S; Agarwal A; Ventresca M; Tang S; Morgano GP; Wang M; Ahmed MM; Neumann I; Izcovich A; Criniti J; Popoff F; Devereaux PJ; Dahm P; Anderson D; Lavikainen LI; Tikkinen KAO; Guyatt GH; Schünemann HJ; Violette PD
BMJ; 2022 Mar; 376():e066785. PubMed ID: 35264372
[TBL] [Abstract][Full Text] [Related]
36. Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials.
Brunetti ND; Tricarico L; Correale M; De Gennaro L; Santoro F; Ieva R; Di Biase M
J Thromb Thrombolysis; 2020 Aug; 50(2):305-310. PubMed ID: 31654194
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
38. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.
Huang J; Cao Y; Liao C; Wu L; Gao F
Thromb Haemost; 2011 Feb; 105(2):245-53. PubMed ID: 20941455
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Direct Oral Anticoagulants for Secondary Prevention of Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies.
Wang Y; Lv H; Li D; Chen C; Gu G; Sun Y; Yang X; Liu Y; Fang F; Liu J; Tse G; Xia Y
Front Pharmacol; 2019; 10():773. PubMed ID: 31354488
[No Abstract] [Full Text] [Related]
40. Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis.
Dong S; Zhang Y; Li Y; Li Y; Miao Y; Zhao R; Zhai S
Ann Pharmacother; 2021 Apr; 55(4):430-439. PubMed ID: 32938202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
